Welcome
Cardiorentis is a privately owned biopharmaceutical company designed for the new world of drug development
Acute heart failure
AHF can be defined as the sudden or gradual onset of the signs or symptoms of heart failure resulting in a need for urgent therapy or hospitalisation.
Ularitide
Ularitide is an advanced natriuretic peptide in Phase III development as an intravenous (IV) infusion treatment for acute heart failure (AHF).
Welcome to Cardiorentis AG
Cardiorentis AG is a privately owned pharmaceutical company based in Zug, Switzerland.
Focused, fast moving, flexible, with patients at its heart, Cardiorentis
is committed to introducing the first therapy with proven outcome
benefits for patients with acute heart failure and developing innovative
medicines for diseases of high unmet medical need.
Latest News
-
28-01-2015
Join Us
At HF 2015 23rd – 26th May in Seville, Spain.
Visit our Stand D10 to find out the latest on the TRUE-AHF trial.
-
16-10-2014
Press release
Cardiorentis AG and Roche Announce Collaboration to Establish Therapeutic Impact of Ularitide